Middle East and Africa Liver Fibrosis Treatment Market Report Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Middle East And Africa Liver Fibrosis Treatment Market

Market Size in USD Billion

CAGR : 12.30 %

Bar chart comparing the Middle East And Africa Liver Fibrosis Treatment Market size in 2024 - 935.44 and 2032 - 2354.75, highlighting the projected market growth.

USD 935.44 Million USD 2,354.75 Million 2024 2032

Forecast Period	2025 –2032
Market Size (Base Year)	USD 935.44 Million
Market Size (Forecast Year)	USD 2,354.75 Million
CAGR	12.30 %
Major Markets Players	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

Middle East and Africa Liver Fibrosis Treatment Market, By Treatment Type (Medication and Surgery/Therapy), Stages ( F2, F1, F3, and F4), Indication (Non-Alcoholic Steatohepatitis (NASH), Hepatitis B & C-Induced Fibrosis, Alcoholic Liver Disease (ALD), Autoimmune Liver Diseases, Genetic Disorders, and Others), Gender(Male and Female), End User (Hospitals, Specialty Clinics, Clinics, Ambulatory and Research Centers, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends & Forecast To 2032

Middle East and Africa Liver Fibrosis Treatment Market Size

Middle East and Africa liver fibrosis treatment market was valued at USD 935.44 million in 2024 and is expected to reach USD 2,354.75 million by 2032
During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 12.3%, primarily driven by the increasing consumer awareness of natural health solutions
This growth is driven by factors such as increasing prevalence of liver diseases. In addition, affordability drives rising consumption of alcohol.

Middle East and Africa Liver Fibrosis Treatment Market Analysis

The growing number of liver diseases creates a larger patient population in need of effective therapeutic options, particularly for conditions such as hepatitis B and C. Contributing factors such as rising alcohol consumption, unhealthy dietary habits, and an increase in obesity rates have all led to more people being diagnosed with these liver conditions
As liver damage advances, the risk of developing liver fibrosis increases, placing a significant burden on healthcare systems to offer effective treatment options. This growing demand drives the development and availability of targeted therapies, fueling market growth as healthcare providers seek innovative solutions for managing this condition
Moreover, increased awareness among healthcare practitioners and the general public has led to more individuals being screened and diagnosed at earlier stages of liver disease. Advancements in diagnostic techniques, including non-invasive imaging and blood tests, have facilitated the identification of liver fibrosis sooner in the disease's progression. This early detection allows for timely interventions, stimulating the demand for innovative treatments that effectively reverse or manage liver fibrosis

For instance, in August 2023, as per an article published by NCBI, liver disease accounts for two million deaths annually and is responsible for 4% of all deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related deaths occur in men. This alarming statistic underscores the urgent need for effective treatment options and highlights the significant public health burden posed by liver diseases, further motivating healthcare systems and pharmaceutical companies to prioritize the development of innovative therapies specifically targeting liver fibrosis and its underlying causes

Consequently, pharmaceutical companies and medical researchers are compelled to invest in developing new therapeutic options, thus propelling the market as stakeholders aim to combat the rising incidence of liver diseases and their associated complications.

Report Scope and Middle East and Africa Liver Fibrosis Treatment Market Segmentation

Attributes	Global Liver Fibrosis Treatment Market Key Market Insights
Segments Covered	By Treatment Type Medication Surgery/Therapy Stages F2 F1 F3 F4 Indication Non-Alcoholic Steatohepatitis (NASH) Hepatitis B and C-Induced Fibrosis Alcoholic Liver Disease (ALD) Autoimmune Liver Diseases Genetic Disorders Others Gender Male Female End User Hospitals Specialty Clinics Clinics Ambulatory and Research Centers Others Distribution Channel Direct Tender Retail Sales
Countries Covered	North America U.S. Canada Mexico Europe Germany France U.K. Italy Spain Switzerland Russia Belgium Netherlands Turkey Poland Sweden Norway Denmark Finland Rest of Europe Asia-Pacific China Japan India South Korea Australia Singapore Thailand Indonesia Malaysia Taiwan New Zealand Philippines Vietnam Rest of Asia-Pacific South America Brazil Argentina Rest of South America Middle East and Africa South Africa Saudi Arabia U.A.E Egypt Israel Kuwait Qatar Oman Rest of Middle East and Africa
Key Market Players	F. Hoffmann-La Roche Ltd (Switzerland) Abbott (U.S.) La Renon Healthcare Pvt. Ltd. (India) GENFIT SA (France) Madrigal Pharmaceuticals (U.S.) Aligos Therapeutics (U.S.) Pfizer Inc. (U.S.) Enanta Pharmaceuticals, Inc. (U.S.) Bristol-Myers Squibb Company (U.S.) Vertex Pharmaceuticals Incorporated (U.S.) Takeda Pharmaceutical Company Limited (Japan) Hepion Pharmaceuticals (U.S.) Echosens (France) Galectin Therapeutics, Inc. (U.S.) Conatus Pharmaceuticals (U.S.) Tvardi Therapeutics (U.S.) Viking Therapeutics (U.S.) Calliditas Therapeutics AB (Sweden) Novomedix (U.S.) Galecto Biotech (Denmark) Pilant Therapeutics, Inc. (U.S.) Sagimet Biosciences (U.S.) Gyre Therapeutics, Inc. (U.S.) Akero Therapeutics, Inc. (U.S.) CureVac SE (Germany) Novo Nordisk A/S (Denmark) Ipsen Pharma (France) AdAlta Limited (Australia) Alentis Therapeutics AG (Switzerland) Gilead Sciences, Inc. (U.S.) AbbVie Inc. (U.S.) Merck and Co., Inc. (U.S.) Novartis AG (Switzerland) Intercept Pharmaceuticals, Inc. (U.S.)
Market Opportunities	Emerging Technologies and Advanced Treatments In Liver Fibrosis Management Progress In Pipeline Products For Liver Fibrosis Treatment Strategic Mergers And Acquisitions Among The Key Players
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Middle East and Africa Liver Fibrosis Treatment Market Trends

“Increasing Prevalence of Liver Diseases”

The increasing prevalence of liver diseases is emerging as a significant Middle East and Africa health concern, contributing substantially to healthcare burdens worldwide
Factors such as excessive alcohol consumption, rising obesity rates, viral hepatitis infections, and unhealthy lifestyles are leading to a surge in conditions like fatty liver disease, cirrhosis, and liver cancer
The growing incidence of non-alcoholic fatty liver disease (NAFLD), particularly linked to diabetes and metabolic syndrome, is also alarming. As a result, there is an increased demand for early diagnosis, effective treatment options, and public health initiatives. This trend is expected to drive innovation and growth in the liver disease treatment market

Middle East and Africa Liver Fibrosis Treatment Market Dynamics

Drivers

“Rising Consumption of Alcohol”

Rising alcohol consumption is a significant contributor to the Middle East and Africa liver fibrosis treatment market due to its direct correlation with the incidence of liver diseases, particularly Alcoholic Liver Disease (ALD)
As more individuals consume alcohol regularly and in larger quantities, the risk of developing liver-related complications, including liver fibrosis and cirrhosis, increases significantly
Chronic alcoholism leads to inflammation, fat accumulation, and, ultimately, fibrosis as the liver undergoes repeated damage and repair
This growing prevalence of alcohol-related liver conditions creates a pressing demand for effective treatments and management strategies to help mitigate liver damage and improve patient outcomes

For instance,

In October 2024, as per an article published by the International Journal of Mental Health Systems, the prevalence of alcohol consumption was 54.5% and 47.7% at the baseline and follow-up, respectively. Moreover, 12% of men reported to have newly started drinking. This prevalence of alcohol consumption leads to an increased incidence of liver fibrosis Middle East and Africaly, potentially impacting market growth
In June 2024, as per STAT, alcohol-related deaths are on the rise, and experts are particularly concerned about an increase among young people and women. The U.S. saw a 25.5% spike in alcohol-related deaths between 2019 and 2020 — accounting for 3% of all deaths. Moreover, the largest increases in alcohol-related deaths were among people 25 to 34 and 35 to 44 years old, wherein deaths in both groups increased by over 37%
Moreover, the increasing societal acceptance and normalization of alcohol consumption, particularly in younger demographics, further exacerbate the issue, leading to a greater number of individuals at risk for liver fibrotic changes
This trend promotes the growth of the liver fibrosis treatment market and emphasizes the importance of public health initiatives aimed at reducing alcohol consumption and preventing liver disease

Opportunities

“Emerging Technologies and Advanced Treatments in Liver Fibrosis Management”

Emerging technologies like gene therapy, targeted molecular therapies, and biologic agents are transforming the treatment landscape
Recent innovations focus on drugs that specifically target fibrosis progression pathways, such as FXR agonists, TGF-β inhibitors, and anti-inflammatory agents. In addition, non-invasive diagnostic tools like elastography are improving early detection
These advancements offer more effective, personalized treatments for conditions such as NASH (Non-Alcoholic Steatohepatitis) and cirrhosis, leading to better patient outcomes

In February 2024, an article published in Springer Nature, The article reviews emerging approaches for diagnosing and inhibiting liver fibrogenesis. Advances include non-invasive biomarkers, imaging technologies, and cell therapies like mesenchymal stem cells. Promising antifibrotic drugs, including pirfenidone and obeticholic acid, along with innovations in tissue engineering, nanotechnology, and microfluidic models, show potential for personalized, precision treatments
A September 2021, article by NCBI highlighted that Emerging technologies in liver fibrosis treatment focus on advanced therapies targeting molecular pathways like hepatic stellate cell activation. Innovations such as gene therapy, biologics, small molecule inhibitors, and non-invasive diagnostics improve early detection and treatment. Stem cell therapies and tissue engineering also offer promise for reversing fibrosis and enhancing recovery

With the continuous evolution of treatment strategies and diagnostic technologies, liver fibrosis therapies are advancing rapidly
These innovations provide hope for better management of liver diseases, ensuring that patients have access to more effective, personalized treatments with fewer side effects, ultimately improving Middle East and Africa health outcomes

Restraints/Challenge

“Limited Awareness of Liver Diseases”

Limited awareness of liver diseases hinders early diagnosis and appropriate intervention. Many individuals remain unaware of the risk factors and symptoms associated with liver conditions, often attributing vague signs of illness to other, less serious issues
This lack of knowledge delays medical consultations until the disease progresses to advanced stages, such as liver fibrosis or cirrhosis, where treatment options become more complex and less effective
Consequently, late-stage diagnoses reduce the potential for successful treatment outcomes and restrict the overall market growth by limiting the patient population seeking timely care

For instance,

In April 2024, Lupin stated that the patients are unaware of their condition until the disease reaches a critical stage, triggering an urgent need to reassess the approach to liver health awareness, detection, and management. However, a significant hurdle in liver health management lies in the limited understanding of liver diseases and associated risk factors
In July 2021, according to a study that included 11,700 adults (18+ years old) from five National Health and Nutrition Examination Surveys, nearly 96% of adults with NAFLD in the U.S. were unaware they had liver disease, especially among young adults. Therefore, enhancing awareness and education about liver health is crucial for improving patient outcomes and fostering a more proactive approach to liver fibrosis management and treatment market expansion
In January 2021, Springer Nature reported that among the 825 patients included in the research analysis carried out in the research paper, ‘Lack of awareness of liver organ damage in patients with type 2 diabetes’, 8.1% (95% CI 5.1%-12.7%) of patients with steatosis were aware of having a liver condition. Moreover, in a nationally representative sample of U.S. adults with T2DM, the prevalence of advanced liver fibrosis is high. Less than 20% of those with advanced fibrosis are aware of having any liver condition
Limited awareness hampers potential treatment outcomes for patients and stifles market growth by reducing the number of individuals engaging with healthcare services early on
Thus, increasing awareness and education about liver health is crucial for improving early diagnosis, enhancing treatment efficacy, and ultimately fostering a more robust market for liver fibrosis therapies

Middle East and Africa Liver Fibrosis Treatment Market Scope

The market is segmented on the basis product type, treatment, basis of source, application, route of administration, mode of purchase, age group, gender, end user, and distribution channel.

Segmentation	Sub-Segmentation
By Treatment Type	Treatment Type Medication Surgery/Therapy
By Stages	Stages F2 F1 F3 F4
By Indication	Indication Non-Alcoholic Steatohepatitis (NASH) Hepatitis B and C-Induced Fibrosis Alcoholic Liver Disease (ALD) Autoimmune Liver Diseases Genetic Disorders Others.
By End User	End User Hospitals Specialty Clinics Clinics Ambulatory and Research Centers Others
By Distribution Channel	Distribution Channel Direct Tender Retail Sales

“Saudi Arabia is the Dominant Country in the Liver Fibrosis Treatment Market ”

Saudi Arabia leads the liver fibrosis treatment market in the Middle East & Africa, driven by a high prevalence of liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and hepatitis C, alongside a strong focus on healthcare modernization under the Vision 2030 initiative
The country boasts a rapidly evolving healthcare infrastructure, with significant government investments in specialized liver clinics, advanced diagnostic technologies, and non-invasive treatment modalities
Widespread screening programs, coupled with increased patient awareness and education, have boosted early detection rates, further driving demand for effective liver fibrosis therapies.
Saudi Arabia’s national health strategy emphasizes combating chronic liver diseases through preventive care, research, and better disease management protocols

“Saudi Arabia is Projected to Register the Highest Growth Rate”

Saudi Arabia is expected to be the fastest growing country in the market due to due to the adoption of cutting-edge biomarkers, increased availability of innovative antifibrotic therapies, and growing involvement of Middle East and Africa pharmaceutical companies
These factors collectively position Saudi Arabia as both the largest and fastest-growing market for liver fibrosis treatment in the Middle East & Africa, serving as a model for regional healthcare transformation

Middle East and Africa Liver Fibrosis Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

F. Hoffmann-La Roche Ltd (Switzerland)
Abbott (U.S.)
La Renon Healthcare Pvt. Ltd. (India)
GENFIT SA (France)
Madrigal Pharmaceuticals (U.S.)
Aligos Therapeutics (U.S.)
Pfizer Inc. (U.S.)
Enanta Pharmaceuticals, Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Vertex Pharmaceuticals Incorporated (U.S.)
Takeda Pharmaceutical Company Limited (Japan)
Hepion Pharmaceuticals (U.S.)
Echosens (France)
Galectin Therapeutics, Inc. (U.S.)
Conatus Pharmaceuticals (U.S.)
Tvardi Therapeutics (U.S.)
Viking Therapeutics (U.S.)
Calliditas Therapeutics AB (Sweden)
Novomedix (U.S.)
Galecto Biotech (Denmark)
Pilant Therapeutics, Inc. (U.S.)
Sagimet Biosciences (U.S.)
Gyre Therapeutics, Inc. (U.S.)
Akero Therapeutics, Inc. (U.S.)
CureVac SE (Germany)
Novo Nordisk A/S (Denmark)
Ipsen Pharma (France)
AdAlta Limited (Australia)
Alentis Therapeutics AG (Switzerland)
Gilead Sciences, Inc. (U.S.)
AbbVie Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Novartis AG (Switzerland)
Intercept Pharmaceuticals, Inc. (U.S.)

Latest Developments in Middle East and Africa Liver Fibrosis Treatment Market

In June 2024, Gilead Sciences presented the new research at the 2024 Middle East and Africaan Association for the Study of the Liver (EASL) Congress in Milan, focusing on liver diseases such as primary biliary cholangitis (PBC), hepatitis B (HBV), hepatitis delta virus (HDV), and others. Key presentations will include long-term data from the ASSURE study on seladelpar for PBC, results on tenofovir for liver cancer prevention in HBV, and findings from the MYR204 and MYR301 studies on Hepcludex for HDV. This research highlights Gilead's commitment to advancing treatment options for liver diseases
In October 2024, Intercept Pharmaceuticals, Inc discussed their ongoing efforts to explore racial differences and disparities in Primary Biliary Cholangitis (PBC) care. The company is addressing how various populations may face different challenges in the diagnosis, treatment, and management of PBC. By exploring these disparities, Intercept aims to improve access to care and treatment outcomes for all patients, potentially reducing barriers to effective treatment of liver diseases, including fibrosis
In November 2022, The U.S. Food and Drug Administration (FDA) approved Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus (HBV) infection in pediatric patients aged 12 years and older with compensated liver disease. This approval extends the use of Vemlidy, which was initially approved in 2016 for adults with chronic HBV. The approval is based on a Phase 2 clinical trial demonstrating Vemlidy’s efficacy and safety in this younger patient group
In September 2022, Gilead Sciences completed its acquisition of MiroBio, a UK-based biotechnology company focused on restoring immune balance through agonists targeting immune inhibitory receptors. The acquisition, valued at approximately $405 million, provides Gilead with MiroBio’s discovery platform and its portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, targets immune cells to suppress inflammatory immune responses and is currently in Phase 1 clinical trials. This acquisition enhances Gilead's efforts in addressing chronic immune-mediated conditions
In March 2021, Gilead Sciences and Novo Nordisk expanded their collaboration in the treatment of non-alcoholic steatohepatitis (NASH) by initiating a Phase 2b clinical trial. The study investigates the safety and efficacy of semaglutide, a GLP-1 receptor agonist from Novo Nordisk, combined with Gilead's cilofexor (an FXR agonist) and firsocostat (an ACC inhibitor) in patients with cirrhosis due to NASH. The trial will assess the treatments' impact on liver fibrosis and NASH resolution, with recruitment expected to start in the second half of 2021

SKU-73831

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 TREATMENT TYPE LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS FIVE FORCES ANALYSIS

4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY

4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY

4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY

4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY

4.3 EPIDEMIOLOGY

4.3.1 INCIDENCE OF ALL BY GENDER

4.3.2 TREATMENT RATE

4.3.3 TREATMENT RATE

4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

4.3.5 PATIENT TREATMENT SUCCESS RATES

4.4 MARKETED DRUG ANALYSIS

4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

4.5.1 PATIENT FLOW DIAGRAM

4.5.2 KEY PRICING STRATEGIES

4.5.3 KEY PATIENT ENROLLMENT STRATEGIES

5 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF LIVER DISEASES

6.1.2 RISING CONSUMPTION OF ALCOHOL

6.1.3 RISING LIVER TRANSPLANTATION RATES

6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH

6.2 RESTRAINTS

6.2.1 LIMITED AWARENESS OF LIVER DISEASES

6.2.2 REGULATORY CHALLENGES

6.3 OPPORTUNITIES

6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT

6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT

6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS

6.4 CHALLENGES

6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS

6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE

7 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 MEDICATION

7.2.1 ANTIVIRAL AGENTS

7.2.1.1 VELPATASVIR/SOFOSBUVIR

7.2.1.2 TENOFOVIR

7.2.1.3 LEDIPASVIR/SOFOSBUVIR

7.2.1.4 SOFOSBUVIR

7.2.1.5 ENTECAVIR

7.2.2 ANTIFIBROTIC AGENTS

7.2.2.1 OBETICHOLIC ACID

7.2.2.2 TGF-Β INHIBITORS

7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS

7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS

7.2.2.5 OTHERS

7.2.3 ANTI-INFLAMMATORY DRUGS

7.2.3.1 CORTICOSTEROIDS

7.2.3.1.1 PREDNISONE

7.2.3.1.2 DEXAMETHASONE

7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS

7.2.3.2.1 INFLIXIMAB

7.2.3.2.2 ETANERCEPT

7.2.3.3 INTERLEUKIN (IL) INHIBITORS

7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB)

7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA)

7.2.4 IMMUNOSUPPRESSANTS

7.2.4.1 MYCOPHENOLATE MOFETIL

7.2.4.2 TACROLIMUS

7.2.4.3 CYCLOSPORINE

7.2.5 MARKETED DRUGS

7.2.5.1 VELPATASVIR/SOFOSBUVIR

7.2.5.2 TENOFOVIR

7.2.5.3 LEDIPASVIR/SOFOSBUVIR

7.2.5.4 OBETICHOLIC ACID (OCA)

7.2.5.5 SOFOSBUVIR

7.2.5.6 PIRFENIDONE

7.2.5.7 OTHERS

7.2.6 PIPELINE DRUGS

7.2.7 BRANDED DRUGS

7.2.7.1 EPCLUSA

7.2.7.2 VIREAD AND VEMLIDY

7.2.7.3 OCALIVA

7.2.7.4 HARVONI

7.2.7.5 SOVALDI

7.2.7.6 BARACLUDE

7.2.7.7 ACTOS

7.2.7.8 OTHERS

7.2.8 GENERIC DRUGS

7.2.9 ORAL

7.2.10 PARENTERAL

7.2.11 OTHERS

7.3 SURGERY/THERAPY

7.3.1 LIVER TRANSPLANTATION

7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT)

7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT)

7.3.4 SPLIT LIVER TRANSPLANTATION

7.3.5 DOMINO LIVER TRANSPLANT

7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES

7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL)

7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)

7.3.6.3 LIVER ABLATION PROCEDURES

7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA)

7.3.6.3.2 MICROWAVE ABLATION (MWA)

7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION)

7.3.7.1 SEGMENTAL RESECTION

7.3.7.2 LOBECTOMY

7.3.7.3 WEDGE RESECTION

7.3.8 CELL-BASED THERAPY

7.3.8.1 STEM CELL THERAPY

7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS)

7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS)

7.3.8.2 GENE THERAPY

7.3.8.2.1 CRISPR-BASED LIVER REGENERATION

7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS

7.3.8.2.3 SIRNA-BASED THERAPIES

7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS

7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS

7.3.8.2.4.2 EMRICASAN

7.3.8.2.4.3 PENTOXIFYLLINE

7.3.8.2.4.4 LOSARTAN

7.3.8.2.4.5 METHYL FERULIC ACID

7.3.8.2.4.6 OTHERS

7.4 OTHERS

8 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES

8.1 OVERVIEW

8.2 F2

8.3 F1

8.4 F3

8.5 F4

9 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION

9.1 OVERVIEW

9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH)

9.3 HEPATITIS B & C-INDUCED FIBROSIS

9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS

9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS

9.4 ALCOHOLIC LIVER DISEASE (ALD)

9.5 AUTOIMMUNE LIVER DISEASES

9.5.1 AUTOIMMUNE HEPATITIS (AIH)

9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC)

9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC)

9.6 GENETIC DISORDERS

9.6.1 HEMOCHROMATOSIS

9.6.2 WILSON’S DISEASE

9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY

9.7 OTHERS

10 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER

10.1 OVERVIEW

10.2 MALE

10.2.1 40-55 YEARS

10.2.2 ABOVE 55 YEARS

10.2.3 BELOW 40 YEARS

10.3 FEMALE

10.3.1 ABOVE 55 YEARS

10.3.2 40-55 YEARS

10.3.3 BELOW 40 YEARS

11 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.2.1 PUBLIC HOSPITALS

11.2.2 PRIVATE HOSPITALS

11.3 SPECIALTY CLINICS

11.3.1 HEPATOLOGY CLINICS

11.3.2 GASTROENTEROLOGY CLINICS

11.4 CLINICS

11.5 AMBULATORY AND RESEARCH CENTERS

11.6 OTHERS

12 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.2.1 RETAIL SALES

12.2.1.1 HOSPITAL PHARMACY

12.2.1.2 RETAIL PHARMACY

12.2.1.3 ONLINE PHARMACY

13 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY REGION

13.1 MIDDLE EAST AND AFRICA

13.1.1 SOUTH AFRICA

13.1.2 SAUDI ARABIA

13.1.3 U.A.E

13.1.4 EGYPT

13.1.5 ISRAEL

13.1.6 KUWAIT

13.1.7 QATAR

13.1.8 OMAN

13.1.9 REST OF MIDDLE EAST AND AFRICA

14 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

15 SWOT ANALYSIS

16 COMPANY PROFILES

16.1 GILEAD SCIENCES, INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT/NEWS

16.2 ABBVIE, INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 MERCK & CO, INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 NOVARTIS AG

16.4.1 COMPANY SNAPSHOTS

16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 PIPELINE PRODUCT PORTFOLIO

16.4.6 RECENT DEVELOPMENT

16.5 INTERCEPT PHARMACEUTICALS, INC.

16.5.1 COMPANY SNAPSHOTS

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 PIPELINE PRODUCT PORTFOLIO

16.5.6 RECENT NEWS

16.6 ABBOTT

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 1.1.5 RECENT DEVELOPMENT

16.7 ALIGOS THERAPEUTICS

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 ALNICHE LIFE SCIENCES PVT. LTD.

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 ALENTIS THERAPEUTICS AG

16.9.1 COMPANY SNAPSHOT

16.9.2 PIPELINE PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 ADALTA LIMITED

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PIPELINE PRODUCT PORTFOLIO

16.10.4 RECENT NEWS

16.11 AKERO THERAPEUTICS, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PIPELINE PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 BRISTOL-MYERS SQUIBB

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 CALLIDITAS THERAPEUTICS AB

16.13.1 COMPANY SNAPSHOT

16.13.2 PIPELINE PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 CUREVAC SE

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 CONATUSPHARMA

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT/NEWS

16.16 ENANTA PHARMACEUTICALS, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 ECHOSENS

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT/NEWS

16.18 F. HOFFMANN-LA ROCHE LTD

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 COMPANY SHARE ANALYSIS

16.18.4 PRODUCT PORTFOLIO

16.18.5 RECENT DEVELOPMENT

16.19 GALECTO BIOTECH

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PIPELINE PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT/NEWS

16.2 GALECTIN THERAPEUTICS, INC.

16.20.1 COMPANY SNAPSHOTS

16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS

16.20.3 PIPELINE PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

16.21 GYRE THERAPEUTICS, INC.

16.21.1 COMPANY SNAPSHOT

16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.21.3 PRODUCT PORTFOLIO

16.21.4 RECENT DEVELOPMENT/NEWS

16.22 GENFIT SA

16.22.1 COMPANY SNAPSHOTS

16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.22.3 PIPELINE PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPMENT

16.23 HEPION PHARMACEUTICALS

16.23.1 COMPANY SNAPSHOT

16.23.2 REVENUE ANALYSIS

16.23.3 PIPELINE PORTFOLIO

16.23.4 RECENT DEVELOPMENT

16.24 IPSEN PHARMA

16.24.1 COMPANY SNAPSHOT

16.24.2 REVENUE ANALYSIS

16.24.3 PIPELINE PRODUCT PORTFOLIO

16.24.4 RECENT NEWS/DEVELOPMENTS

16.25 LA RENON HEALTHCARE PVT. LTD.

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENT

16.26 MADRIGAL PHARMACEUTICALS

16.26.1 COMPANY SNAPSHOTS

16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.26.3 PRODUCT PORTFOLIO

16.26.4 RECENT DEVELOPMENT

16.27 NOVO NORDISK A/S

16.27.1 COMPANY SNAPSHOT

16.27.2 REVENUE ANALYSIS

16.27.3 PIPELINE PRODUCT PORTFOLIO

16.27.4 RECENT DEVELOPMENT

16.28 NOVOMEDIX

16.28.1 COMPANY SNAPSHOT

16.28.2 PIPELINE PRODUCT PORTFOLIO

16.28.3 RECENT DEVELOPMENT

16.29 PILANT THERAPEUTICS, INC.

16.29.1 COMPANY SNAPSHOT

16.29.2 REVENUE ANALYSIS

16.29.3 PIPELINE PRODUCT PORTFOLIO

16.29.4 RECENT NEWS

16.3 PFIZER INC.

16.30.1 COMPANY SNAPSHOT

16.30.2 REVENUE ANALYSIS

16.30.3 PIPELINE PRODUCT PORTFOLIO

16.30.4 RECENT DEVELOPMENT/NEWS

16.31 SAGIMET BIOSCIENCES

16.31.1 COMPANY SNAPSHOTS

16.31.2 REVENUE ANALYSIS

16.31.3 1.1.4 PRODUCT PORTFOLIO

16.31.4 RECENT DEVELOPMENT/NEWS

16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED

16.32.1 COMPANY SNAPSHOT

16.32.2 REVENUE ANALYSIS

16.32.3 PIPELINE PRODUCT PORTFOLIO

16.32.4 PRODUCT PORTFOLIO

16.32.5 RECENT DEVELOPMENT

16.33 TVARDI THERAPEUTICS

16.33.1 COMPANY SNAPSHOT

16.33.2 PIPELINE PRODUCT PORTFOLIO

16.33.3 RECENT DEVELOPMENT/NEWS

16.34 VERTEX PHARMACEUTICALS INCORPORATED

16.34.1 COMPANY SNAPSHOT

16.34.2 REVENUE ANALYSIS

16.34.3 PRODUCT PORTFOLIO

16.34.4 RECENT DEVELOPMENT

16.35 VIKING THERAPEUTICS

16.35.1 COMPANY SNAPSHOT

16.35.2 REVENUE ANALYSIS

16.35.3 PIPELINE PRODUCT PORTFOLIO

16.35.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST AND AFRICA INCIDENCE OF CIRRHOSIS BY GENDER (2019)

TABLE 2 TREATMENT ADHERENCE LEVELS IN LIVER DISEASE PATIENTS

TABLE 3 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 4 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 7 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 9 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 10 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 12 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 13 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 15 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 16 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 17 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 19 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 20 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 22 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 23 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 24 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 25 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 26 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 27 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 28 MIDDLE EAST AND AFRICA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 29 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 MIDDLE EAST AND AFRICA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 32 MIDDLE EAST AND AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 MIDDLE EAST AND AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 MIDDLE EAST AND AFRICA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 MIDDLE EAST AND AFRICA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 36 MIDDLE EAST AND AFRICA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 MIDDLE EAST AND AFRICA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 38 MIDDLE EAST AND AFRICA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 MIDDLE EAST AND AFRICA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 MIDDLE EAST AND AFRICA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 MIDDLE EAST AND AFRICA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 43 MIDDLE EAST AND AFRICA F2 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 44 MIDDLE EAST AND AFRICA F1 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 MIDDLE EAST AND AFRICA F3 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 46 MIDDLE EAST AND AFRICA F4 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 47 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 48 MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 49 MIDDLE EAST AND AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 50 MIDDLE EAST AND AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 MIDDLE EAST AND AFRICA ALCOHOLIC LIVER DISEASE (ALD) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 52 MIDDLE EAST AND AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 MIDDLE EAST AND AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 55 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 MIDDLE EAST AND AFRICA OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 57 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 58 MIDDLE EAST AND AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 59 MIDDLE EAST AND AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 60 MIDDLE EAST AND AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 61 MIDDLE EAST AND AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 63 MIDDLE EAST AND AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 64 MIDDLE EAST AND AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 66 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 MIDDLE EAST AND AFRICA CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 68 MIDDLE EAST AND AFRICA AMBULATORY AND RESEARCH CENTERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 69 MIDDLE EAST AND AFRICA OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 70 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 71 MIDDLE EAST AND AFRICA DIRECT TENDER IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 72 MIDDLE EAST AND AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 73 MIDDLE EAST AND AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 75 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 78 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 80 MIDDLE EAST AND AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 81 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 83 MIDDLE EAST AND AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 84 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 85 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 86 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 88 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 89 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 90 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 91 MIDDLE EAST AND AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 92 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 93 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 94 MIDDLE EAST AND AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 95 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 97 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 98 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 99 MIDDLE EAST AND AFRICA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 MIDDLE EAST AND AFRICA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 102 MIDDLE EAST AND AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 103 MIDDLE EAST AND AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 104 MIDDLE EAST AND AFRICA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 MIDDLE EAST AND AFRICA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 106 MIDDLE EAST AND AFRICA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 MIDDLE EAST AND AFRICA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 108 MIDDLE EAST AND AFRICA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 MIDDLE EAST AND AFRICA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 MIDDLE EAST AND AFRICA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 MIDDLE EAST AND AFRICA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 113 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 114 MIDDLE EAST AND AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 MIDDLE EAST AND AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 118 MIDDLE EAST AND AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 MIDDLE EAST AND AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 121 MIDDLE EAST AND AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 124 MIDDLE EAST AND AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 128 SOUTH AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 SOUTH AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 130 SOUTH AFRICA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 131 SOUTH AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 SOUTH AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 133 SOUTH AFRICA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 134 SOUTH AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 SOUTH AFRICA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 136 SOUTH AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 SOUTH AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 138 SOUTH AFRICA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 139 SOUTH AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 SOUTH AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 141 SOUTH AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 142 SOUTH AFRICA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 SOUTH AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 144 SOUTH AFRICA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 145 SOUTH AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 SOUTH AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 147 SOUTH AFRICA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 148 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 149 SOUTH AFRICA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 SOUTH AFRICA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 SOUTH AFRICA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 153 SOUTH AFRICA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 SOUTH AFRICA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 SOUTH AFRICA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 156 SOUTH AFRICA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 SOUTH AFRICA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 SOUTH AFRICA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 SOUTH AFRICA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 SOUTH AFRICA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 SOUTH AFRICA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 163 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 164 SOUTH AFRICA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 SOUTH AFRICA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 SOUTH AFRICA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 168 SOUTH AFRICA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 SOUTH AFRICA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 171 SOUTH AFRICA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 172 SOUTH AFRICA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 173 SOUTH AFRICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 174 SOUTH AFRICA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 178 SAUDI ARABIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 SAUDI ARABIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 180 SAUDI ARABIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 181 SAUDI ARABIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 SAUDI ARABIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 183 SAUDI ARABIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 184 SAUDI ARABIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 SAUDI ARABIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 186 SAUDI ARABIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 SAUDI ARABIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 188 SAUDI ARABIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 189 SAUDI ARABIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 SAUDI ARABIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 191 SAUDI ARABIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 192 SAUDI ARABIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 SAUDI ARABIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 194 SAUDI ARABIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 195 SAUDI ARABIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 SAUDI ARABIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 197 SAUDI ARABIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 198 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 199 SAUDI ARABIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 SAUDI ARABIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 SAUDI ARABIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 203 SAUDI ARABIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 SAUDI ARABIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 SAUDI ARABIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 SAUDI ARABIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 SAUDI ARABIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 SAUDI ARABIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 SAUDI ARABIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 SAUDI ARABIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 SAUDI ARABIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 213 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 214 SAUDI ARABIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 SAUDI ARABIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 SAUDI ARABIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 218 SAUDI ARABIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 SAUDI ARABIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 221 SAUDI ARABIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 SAUDI ARABIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 SAUDI ARABIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 224 SAUDI ARABIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 228 U.A.E ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 U.A.E ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 230 U.A.E ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 231 U.A.E ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 U.A.E ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 233 U.A.E ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 234 U.A.E ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 235 U.A.E ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 236 U.A.E CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 U.A.E CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 238 U.A.E CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 239 U.A.E TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 U.A.E TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 241 U.A.E TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 242 U.A.E INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 U.A.E INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 244 U.A.E INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 245 U.A.E IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 U.A.E IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 247 U.A.E IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 248 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 249 U.A.E MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 U.A.E BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 U.A.E MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 253 U.A.E SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 U.A.E LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 U.A.E ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 U.A.E LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 U.A.E PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 U.A.E CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 U.A.E STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 U.A.E GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 261 U.A.E HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 263 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 264 U.A.E HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 U.A.E AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 U.A.E GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 268 U.A.E MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 U.A.E FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 271 U.A.E HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 U.A.E SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 U.A.E LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 274 U.A.E RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 278 EGYPT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 EGYPT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 280 EGYPT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 281 EGYPT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 EGYPT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 283 EGYPT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 284 EGYPT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 EGYPT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 286 EGYPT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 EGYPT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 288 EGYPT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 289 EGYPT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 EGYPT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 291 EGYPT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 292 EGYPT INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 EGYPT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 294 EGYPT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 295 EGYPT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 EGYPT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 297 EGYPT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 298 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 299 EGYPT MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 EGYPT BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 EGYPT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 303 EGYPT SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 EGYPT LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 EGYPT ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 EGYPT LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 EGYPT PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 EGYPT CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 309 EGYPT STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 EGYPT GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 EGYPT HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 313 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 314 EGYPT HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 EGYPT AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 EGYPT GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 318 EGYPT MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 EGYPT FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 321 EGYPT HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 EGYPT SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 EGYPT LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 324 EGYPT RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 328 ISRAEL ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 ISRAEL ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 330 ISRAEL ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 331 ISRAEL ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 ISRAEL ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 333 ISRAEL ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 334 ISRAEL ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 ISRAEL ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 336 ISRAEL CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 ISRAEL CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 338 ISRAEL CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 339 ISRAEL TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 ISRAEL TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 341 ISRAEL TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 342 ISRAEL INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 ISRAEL INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 344 ISRAEL INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 345 ISRAEL IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 ISRAEL IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 347 ISRAEL IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 348 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 349 ISRAEL MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 ISRAEL BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 ISRAEL MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 353 ISRAEL SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 ISRAEL LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 ISRAEL ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 ISRAEL LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 ISRAEL PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 ISRAEL CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 ISRAEL STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 ISRAEL GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 ISRAEL HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 363 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 364 ISRAEL HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 ISRAEL AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 ISRAEL GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 368 ISRAEL MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 ISRAEL FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 371 ISRAEL HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 ISRAEL SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 ISRAEL LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 374 ISRAEL RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 377 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 378 KUWAIT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 KUWAIT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 380 KUWAIT ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 381 KUWAIT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 KUWAIT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 383 KUWAIT ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 384 KUWAIT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 KUWAIT ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 386 KUWAIT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 KUWAIT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 388 KUWAIT CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 389 KUWAIT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 KUWAIT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 391 KUWAIT TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 392 KUWAIT INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 KUWAIT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 394 KUWAIT INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 395 KUWAIT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 KUWAIT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 397 KUWAIT IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 398 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 399 KUWAIT MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 KUWAIT BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 KUWAIT MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 403 KUWAIT SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 KUWAIT LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 KUWAIT ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 KUWAIT LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 KUWAIT PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 KUWAIT CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 KUWAIT STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 KUWAIT GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 KUWAIT HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 413 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 414 KUWAIT HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 KUWAIT AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 KUWAIT GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 418 KUWAIT MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 KUWAIT FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 421 KUWAIT HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 KUWAIT SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 423 KUWAIT LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 424 KUWAIT RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 QATAR LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 427 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 428 QATAR ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 429 QATAR ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 430 QATAR ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 431 QATAR ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 432 QATAR ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 433 QATAR ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 434 QATAR ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 435 QATAR ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 436 QATAR CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 QATAR CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 438 QATAR CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 439 QATAR TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 QATAR TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 441 QATAR TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 442 QATAR INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 QATAR INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 444 QATAR INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 445 QATAR IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 446 QATAR IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 447 QATAR IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 448 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 449 QATAR MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 QATAR BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 QATAR MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 453 QATAR SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 454 QATAR LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 QATAR ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 456 QATAR LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 QATAR PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 458 QATAR CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 QATAR STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 460 QATAR GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 461 QATAR HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 462 QATAR LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 463 QATAR LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 464 QATAR HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 465 QATAR AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 QATAR GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 467 QATAR LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 468 QATAR MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 469 QATAR FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 470 QATAR LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 471 QATAR HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 QATAR SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 QATAR LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 474 QATAR RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 475 OMAN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 477 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 478 OMAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 479 OMAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 480 OMAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 481 OMAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 OMAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 483 OMAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 484 OMAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 485 OMAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 486 OMAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 487 OMAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 488 OMAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 489 OMAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 490 OMAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 491 OMAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 492 OMAN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 493 OMAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 494 OMAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 495 OMAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 496 OMAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 497 OMAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 498 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 499 OMAN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 500 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 501 OMAN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 502 OMAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 503 OMAN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 504 OMAN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 505 OMAN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 506 OMAN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 507 OMAN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 508 OMAN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 509 OMAN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 510 OMAN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 511 OMAN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 512 OMAN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 513 OMAN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 514 OMAN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 515 OMAN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 516 OMAN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 517 OMAN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 518 OMAN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 519 OMAN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 520 OMAN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 521 OMAN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 522 OMAN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 523 OMAN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 524 OMAN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 525 REST OF MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

List of Figure

FIGURE 1 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF LIVER DISEASES IS EXPECTED TO DRIVE THE GROWTH OF MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET FROM 2025 TO 2032

FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET IN 2025-2032

FIGURE 13 TWO SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

FIGURE 14 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 15 STRATEGIC DECISIONS

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET

FIGURE 17 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2024

FIGURE 18 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 19 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)

FIGURE 20 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2024

FIGURE 22 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2025-2032 (USD THOUSAND)

FIGURE 23 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, CAGR (2025-2032)

FIGURE 24 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY STAGES, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2024

FIGURE 26 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2025-2032 (USD THOUSAND)

FIGURE 27 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, CAGR (2025-2032)

FIGURE 28 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2024

FIGURE 30 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)

FIGURE 31 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, CAGR (2025-2032)

FIGURE 32 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2024

FIGURE 34 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 35 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, CAGR (2025-2032)

FIGURE 36 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2024

FIGURE 38 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 39 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 40 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 42 MIDDLE EAST AND AFRICA LIVER FIBROSIS TREATMENT MARKET: COMPANY SHARE 2024 (%)

View Detailed Information

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

What is the current market size of the Middle East and Africa liver fibrosis treatment market?

The Middle East and Africa liver fibrosis treatment market size was valued at USD 935.44 million in 2024.

What is the expected growth rate of Middle East and Africa liver fibrosis treatment market ?

The Middle East and Africa liver fibrosis treatment market is to grow at a CAGR of 12.3 % during the forecast period of 2025 to 2032.

What are the primary segments covered in the Middle East and Africa liver fibrosis treatment market ?

The Middle East and Africa liver fibrosis treatment market is segmented into five notable segments based on treatment type, stages, indication, end user, and distribution channel. On the basis of treatment type, the market is segmented into medication and surgery/therapy. on the basis of stages, the market is segmented into F2, F1, F3, and F4, on the basis of indication, the market is segmented into non-alcoholic steatohepatitis (Nash), hepatitis B and C-induced fibrosis, alcoholic liver disease (ALD), autoimmune liver diseases, genetic disorders, and others. on the basis of gender, the market is segmented into male and female. on the basis of end user, the market is segmented into hospitals, specialty clinics, clinics, ambulatory and research centers, and others. on the basis of distribution channel, the market is segmented into direct tender and retail sales.

Who are major players in Middle East and Africa liver fibrosis treatment ?

Companies such as Gilead Sciences, Inc. (U.S.),AbbVie Inc. (U.S.),Merck and Co., Inc. (U.S.),Novartis AG (Switzerland), Intercept Pharmaceuticals, Inc. (U.S.)are the major companies in the Middle East and Africa liver fibrosis treatment.

Middle East and Africa Liver Fibrosis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Middle East and Africa Liver Fibrosis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Circumvent the Tariff challenges with an agile supply chain Consulting

Middle East And Africa Liver Fibrosis Treatment Market

CAGR : 12.30 %

Middle East and Africa Liver Fibrosis Treatment Market Size

Middle East and Africa Liver Fibrosis Treatment Market Analysis

Middle East and Africa Liver Fibrosis Treatment Market Scope

Middle East and Africa Liver Fibrosis Treatment Market Share

Latest Developments in Middle East and Africa Liver Fibrosis Treatment Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL

David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,

Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions

Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

Business Intelligence and Analytics, Ipsen Biopharm Limited

Competition Analyst, Basler Web

Marketing Director, Buhler Group

COO, A global leader providing Drug Delivery Services

Marketing Director, Philips Healthcare

Product manager, Fujifilms

Investor relations, GE Healthcare

Market Analyst, Medincell

Andrew - Senior Global Marketing Manager, Medtronic (US)

Amarildo - Manager, Global Strategic Alignment MasterCard

Tor Hammer Green Nexus LLc

Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Reports

Market Insights

Support

Solutions

Middle East and Africa Liver Fibrosis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Middle East and Africa Liver Fibrosis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Circumvent the Tariff challenges with an agile supply chain Consulting

Middle East And Africa Liver Fibrosis Treatment Market

CAGR : 12.30 %

Middle East and Africa Liver Fibrosis Treatment Market Size

Middle East and Africa Liver Fibrosis Treatment Market Analysis

Middle East and Africa Liver Fibrosis Treatment Market Scope

Middle East and Africa Liver Fibrosis Treatment Market Share

Latest Developments in Middle East and Africa Liver Fibrosis Treatment Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

Browse Related Pages

Claudio Rondena Group Business Development & Strategic Marketing Director,C.O.C Farmaceutici SRL

David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,

Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions

Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

Business Intelligence and Analytics, Ipsen Biopharm Limited

Competition Analyst, Basler Web

Marketing Director, Buhler Group

COO, A global leader providing Drug Delivery Services

Marketing Director, Philips Healthcare

Product manager, Fujifilms

Investor relations, GE Healthcare

Market Analyst, Medincell

Andrew - Senior Global Marketing Manager, Medtronic (US)

Amarildo - Manager, Global Strategic Alignment MasterCard

Tor Hammer Green Nexus LLc

Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL